Y mabs Therapeutics inc
Business Description
Ymabs Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company was founded in 2015 and is headquartered in New York City, New York.
Ymabs Therapeutics focuses on developing monoclonal antibodies that target specific cancer antigens with the goal of providing safer and more effective treatment options for patients. Monoclonal antibodies are laboratory-produced molecules that can mimic the immune system*s ability to fight cancer cells.
The company*s flagship product, naxitamab, is an anti-GD2 monoclonal antibody which has shown promising results in preclinical and clinical studies for the treatment of neuroblastoma, a rare and aggressive type of cancer that primarily affects children. Naxitamab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Ymabs Therapeutics is also developing omburtamab, another anti-GD2 monoclonal antibody, for the treatment of central nervous system/leptomeningeal metastases of neuroblastoma. This therapy aims to address the spread of neuroblastoma to the brain and spinal cord. Omburtamab has shown promising results in clinical trials and has received Fast Track designation from the FDA.
In addition to its neuroblastoma pipeline, Ymabs Therapeutics is exploring the potential of its antibodies in other types of cancer, including osteosarcoma, desmoplastic small round-cell tumor, melanoma, and glioblastoma. The company*s innovative approach involves leveraging the unique properties of its antibodies to specifically target cancer cells while sparing healthy cells, thereby minimizing side effects.
Ymabs Therapeutics operates with a focus on scientific innovation, rigorous clinical development, and a patient-centric approach. The company collaborates with academic institutions, pharmaceutical companies, and research organizations to advance its pipeline and accelerate the development of new treatments.
Overall, Ymabs Therapeutics is committed to improving the outcomes for patients with cancer through the development of novel antibody-based therapies. With its dedication to innovation and collaboration, the company aims to make significant contributions to the field of oncology and provide hope to patients and their families.
|